Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

This study has been completed.
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002031
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: February 1990

November 2, 1999
June 23, 2005
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00002031 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)
Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

To evaluate the effect of application of Dinitrochlorobenzene (DNCB) on the number, morphology, and antigen expression of epidermal Langerhans cells in AIDS and AIDS related complex (ARC) patients.

Not Provided
Interventional
Not Provided
Primary Purpose: Treatment
HIV Infections
Drug: Dinitrochlorobenzene
Not Provided
Stricker RB, Elswood BF. Dendritic cells and dinitrochlorobenzene (DNCB): a new treatment approach to AIDS. Immunol Lett. 1991 Aug;29(3):191-6. Review. Erratum in: Immunol Lett 1992 Aug;33(3):316.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria

Patients must have the following:

  • Stage III or IV HIV infection.
  • Provide informed consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Kaposi's sarcoma lesions in the proposed treatment sites.
  • Liable to require radiation or chemotherapy during the course of the study.
  • Not likely to survive the length of the study.
  • Obvious ultra-violet-irradiated skin damage in the treatment areas and anyone with recent UV exposure or likely to have such exposure (e.g.:
  • holiday tans obtained in Hawaii, members of UV box tanning salons, etc.) Allergy to lidocaine.

Concurrent Medication:

Excluded:

  • Other Immunomodulators.

Concurrent Treatment:

Excluded:

  • Radiation.

Patients with the following are excluded:

  • Kaposi's sarcoma lesions in the proposed treatment sites.
  • Liable to require radiation or chemotherapy during the course of the study.
  • Not likely to survive the length of the study.
  • Obvious ultra-violet-irradiated skin damage in the treatment areas.
  • Allergy to lidocaine.

Prior Medication:

Excluded:

  • Prior DNCB therapy.
Both
18 Years to 55 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00002031
047A
Not Provided
Not Provided
University of California, San Francisco
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
February 1990

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP